Study puts Jardiance in hot pursuit of AZ’s Farxiga in heart failureThe FDA’s approval of AstraZeneca’s SGLT2 inhibitor Farxiga in heart failure was a first for the class, but Share XStudy puts Jardiance in hot pursuit of AZ’s Farxiga in heart failurehttps://pharmaphorum.com/news/study-puts-jardiance-in-hot-pursuit-of-azs-farxiga-in-heart-failure/
Janssen taps wearable tech in Invokana heart failure trialJanssen’s Invokana is playing catch-up in the emerging heart failure market for SGLT2 inhibitors, but hopes a real-world Share XJanssen taps wearable tech in Invokana heart failure trialhttps://pharmaphorum.com/news/janssen-taps-wearable-tech-in-invokana-heart-failure-trial/
Boehringer, Lilly start acute heart failure trial with JardianceBoehringer and Eli Lilly have started a large-scale trial of their diabetes drug Jardiance in acute heart failure, Share XBoehringer, Lilly start acute heart failure trial with Jardiancehttps://pharmaphorum.com/news/boehringer-lilly-start-acute-heart-failure-trial-with-jardiance/
AZ’s Forxiga gets heart claim data on its EU labelAstraZeneca has been cleared to include cardiovascular and kidney outcomes data on the label of its type 2 Share XAZ’s Forxiga gets heart claim data on its EU labelhttps://pharmaphorum.com/news/azs-forxiga-gets-heart-claim-data-on-its-eu-label/
FDA fast-tracks Lilly/Boehringer’s Jardiance for heart failureEli Lilly and Boehringer Ingelheim’s Jardiance was the first diabetes drug to lower the risk of cardiovascular disease Share XFDA fast-tracks Lilly/Boehringer’s Jardiance for heart failurehttps://pharmaphorum.com/news/fda-fast-tracks-lilly-boehringers-jardiance-for-heart-failure/
FDA warns of genital gangrene risk with diabetes drug classThe US regulator released an official risk warning of a rare genital infection identified in 12 patients, including Share XFDA warns of genital gangrene risk with diabetes drug classhttps://pharmaphorum.com/news/risk-sglt2-inhibitors-fda-warns/
SGLT2 inhibitors: an emerging option for cardiologists?With studies showing potential for SGLT2 inhibitors in heart failure, a study of HCP online conversations reveals cardiologists Share XSGLT2 inhibitors: an emerging option for cardiologists?https://pharmaphorum.com/views-and-analysis/sglt2-inhibitors-cardiologists-option/
AZ’s diabetes combination Qtern approved in EuropeThe European Commission has granted marketing approval to a new combination pill from AstraZeneca to treat type 2 Share XAZ’s diabetes combination Qtern approved in Europehttps://pharmaphorum.com/transversal-categories/uk-and-europe/azs-diabetes-combination-qtern-approved-europe/
